(2019) The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. pp. 258-267. ISSN 0269-4727
Full text not available from this repository.
Abstract
What is known and objective Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury. Some animal studies suggest that alpha-lipoic acid (ALA) can improve disease outcome. The aim of this study was to investigate the effects of ALA supplementation on liver enzymes and inflammatory markers in obese patients with NAFLD. Methods In the current randomized, double-blind, placebo-controlled clinical trial, 50 obese patients with NAFLD were randomly allocated to either "ALA"(received 1200 mg ALA as two capsules per day plus 400 mg vitamin E) or "placebo"(received placebo containing starch, as two capsules per day plus 400 mg vitamin E) groups for 12 weeks. Body composition and anthropometric measures, serum levels of liver enzymes, adiponectin, interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and ferritin were measured at baseline and the end of the study. Results and discussion A total number of 45 patients completed the study (ALA group = 23; placebo group = 22). The serum concentration of IL-6 decreased significantly in ALA group in comparison with the placebo group, at end of the study (P = 0.049). Furthermore, ALA intake resulted in a significant increase in serum adiponectin levels compared to placebo (P = 0.008). A significant improvement was observed in liver steatosis grade of the patients in both groups, compared to baseline (P < 0.05). However, there was no difference between the two groups for the changes in liver steatosis, by the end of the study. Body composition and anthropometric measures, liver enzymes, MCP-1 and ferritin serum levels were not significantly different between the study groups, neither at the baseline nor at the end of the study. What is new and conclusion Collectively, ALA supplementation improved serum adiponectin and IL-6 levels, without changing serum liver enzymes and liver steatosis in obese patients with NAFLD.
Item Type: | Article |
---|---|
Keywords: | adiponectin alpha-lipoic acid inflammation liver enzymes non-alcoholic fatty liver obesity adipose-tissue insulin-resistance oxidative stress pathogenesis cytokine exerts injury diet Pharmacology & Pharmacy |
Divisions: | |
Page Range: | pp. 258-267 |
Journal or Publication Title: | Journal of Clinical Pharmacy and Therapeutics |
Volume: | 44 |
Number: | 2 |
Identification Number: | 10.1111/jcpt.12784 |
ISSN: | 0269-4727 |
Depositing User: | مهندس مهدی شریفی |
URI: | http://eprints.zbmu.ac.ir/id/eprint/3703 |
Actions (login required)
View Item |